Should I buy or sell Replimune Group stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks .

What is Replimune Group's stock price target for 2024?

3 brokers have issued 1-year price targets for Replimune Group's shares. Their REPL share price targets range from $13.00 to $52.00. On average, they predict the company's stock price to reach $37.67 in the next year. This suggests a possible upside of 440.4% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts .

How have REPL shares performed in 2024?

Replimune Group's stock was trading at $8.43 at the start of the year. Since then, REPL stock has decreased by 17.3% and is now trading at $6.97. View the best growth stocks for 2024 here .

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our REPL earnings forecast .

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) announced its earnings results on Thursday, February, 8th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.12.

What ETFs hold Replimune Group's stock?

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include First Trust Innovation Leaders ETF (ILDR) . Horizon Kinetics Medical ETF (MEDX) .

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU) , Myovant Sciences (MYOV) , Peabody Energy (BTUUQ) , AVEO Pharmaceuticals (AVEO) , Fate Therapeutics (FATE) , Immunomedics (IMMU) , Pfizer (PFE) , SCYNEXIS (SCYX) , Exelixis (EXEL) and Fulcrum Therapeutics (FULC) .

When did Replimune Group IPO?

Replimune Group (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.11%) and Diversified Trust Co (0.02%). Insiders that own company stock include Colin Love , Fund Iv LP Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito , Philip Astley-Sparke, Robert Coffin , Sushil Patel and Tanya Lewis. View institutional ownership trends .

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:REPL

Replimune Group (REPL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free REPL Stock Alerts

$6.97

-0.24 (-3.33%)

(As of 04/18/2024 ET)

Compare

Today's Range: $6.95
▼
$7.43
50-Day Range: $6.87
▼
$9.03
52-Week Range: $5.89
▼
$24.81

Volume: 1.13 million shs
Average Volume: 1.36 million shs
Market Capitalization: $427.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.67

Get Replimune Group alerts:

Replimune Group MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 440.4% Upside
$37.67 Price Target
Short Interest: Bearish
17.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.28
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.28) to ($2.99) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

113th out of 919 stocks

Biological Products, Except Diagnostic Industry

13th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Replimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Replimune Group has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
17.40% of the float of Replimune Group has been sold short.
Short Interest Ratio / Days to Cover
Replimune Group has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Replimune Group has recently increased by 11.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Replimune Group does not currently pay a dividend.
Dividend Growth
Replimune Group does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Replimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for Replimune Group is -1.28.

3.2

News and Social Media Coverage

News Sentiment
Replimune Group has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Replimune Group this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
9 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Replimune Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Replimune Group are expected to grow in the coming year, from ($3.28) to ($2.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Replimune Group is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Replimune Group is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Replimune Group has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Replimune Group Stock (NASDAQ:REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

REPL Stock News Headlines

April 13, 2024 | americanbankingnews.com

Head to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)

April 7, 2024 | globenewswire.com

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 4, 2024 | globenewswire.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 30, 2024 | bizjournals.com

Five things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is ticking

March 29, 2024 | uk.investing.com

Replimune appoints new CEO ahead of drug application

March 28, 2024 | bizjournals.com

Petri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron deal

March 26, 2024 | marketwatch.com

Replimune Names Sushil Patel as CEO in Broader Shakeup

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | markets.businessinsider.com

Replimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEO

March 26, 2024 | globenewswire.com

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

March 16, 2024 | finance.yahoo.com

REPL Apr 2024 10.000 call

March 15, 2024 | finance.yahoo.com

REPL Mar 2024 10.000 put

March 6, 2024 | finance.yahoo.com

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

March 5, 2024 | finance.yahoo.com

Replimune to Present at Three Upcoming Investor Conferences

February 15, 2024 | markets.businessinsider.com

Positive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials

February 9, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)

February 9, 2024 | msn.com

Replimune Group Is Worried About This – Should You Be Worried Too?

February 8, 2024 | finance.yahoo.com

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

February 8, 2024 | finance.yahoo.com

Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway

February 8, 2024 | investing.com

Replimune Group Inc (REPL)

February 7, 2024 | marketwatch.com

Disc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations Chief

January 23, 2024 | seekingalpha.com

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

December 28, 2023 | finance.yahoo.com

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 17, 2023 | ca.finance.yahoo.com

REPL Feb 2024 30.000 put

December 8, 2023 | markets.businessinsider.com

Balanced Outlook: Replimune’s Setbacks and Potential in Clinical Trials Justify Buy Rating

December 7, 2023 | finance.yahoo.com

An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued

See More Headlines

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/16/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:REPL
CUSIP: N/A
CIK: 1737953
Web: www.replimune.com
Phone: (781) 222-9600
Fax: N/A
Employees: 284
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $37.67
High Stock Price Target: $52.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +422.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-174,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.94%
Return on Assets: -35.80%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 12.40
Quick Ratio: 12.40

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.80 per share
Price / Book: 0.74

Miscellaneous

Outstanding Shares: 61,390,000
Free Float: 48,742,000
Market Cap: $442.62 million
Optionable: Optionable
Beta: 1.21

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Philip Astley-Sparke F.S.A. (Age 53)
CEO & Director
Comp: $1.07M
Dr. Sushil Patel Ph.D. (Age 53)
Chief Strategy Officer
Comp: $665.05k
Dr. Robert Coffin Ph.D. (Age 59)
Founder, President, Chief Research & Development Officer and Director
Comp: $785.89k
Ms. Emily Luisa Hill (Age 44)
Chief Financial Officer
Dr. Colin A. Love Ph.D. (Age 66)
Chief Operating Officer
Comp: $419.37k
Mr. Andrew Schwendenman (Age 48)
Chief Accounting Officer & Treasurer
Dr. Pamela Esposito Ph.D. (Age 50)
Chief Business Officer
Comp: $464.63k
Ms. Tanya N. Lewis M.S. (Age 53)
Chief Development Operations Officer
Comp: $4.7k
Mr. Christopher Sarchi (Age 56)
Chief Commercial Officer
Dr. Konstantinos Xynos M.B.A. (Age 58)
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REPL Stock Analysis - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.
What is Replimune Group's stock price target for 2024?: 3 brokers have issued 1-year price targets for Replimune Group's shares. Their REPL share price targets range from $13.00 to $52.00. On average, they predict the company's stock price to reach $37.67 in the next year. This suggests a possible upside of 440.4% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.
How have REPL shares performed in 2024?: Replimune Group's stock was trading at $8.43 at the start of the year. Since then, REPL stock has decreased by 17.3% and is now trading at $6.97.
View the best growth stocks for 2024 here.
When is Replimune Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024.
View our REPL earnings forecast.
How were Replimune Group's earnings last quarter?: Replimune Group, Inc. (NASDAQ:REPL) announced its earnings results on Thursday, February, 8th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.12.
What ETFs hold Replimune Group's stock?: ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include First Trust Innovation Leaders ETF (ILDR).Horizon Kinetics Medical ETF (MEDX).

What other stocks do shareholders of Replimune Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).
When did Replimune Group IPO?: Replimune Group (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
Who are Replimune Group's major shareholders?: Replimune Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.11%) and Diversified Trust Co (0.02%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis.
View institutional ownership trends.
How do I buy shares of Replimune Group?: Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:REPL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Replimune Group (REPL) Stock Price, News & Analysis

Replimune Group MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Replimune Group Stock (NASDAQ:REPL)

REPL Stock Price History

REPL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

REPL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™